Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute.
Most recently Juno Therapeutics Inc (NASDAQ:JUNO)'s price target was revised on 2/5/17 and according to 12 analysts stock's price will reach at $30.50 during 52 weeks with standard deviation of 9.74. BTIG Research raised shares of Juno Therapeutics from a sell rating to a neutral rating in a report on Thursday, November 3rd. Cowen and Company reissued a "buy" rating and issued a $51.00 price target on shares of Juno Therapeutics in a report on Monday, December 5th. Zacks Investment Research raised Juno Therapeutics from a sell rating to a hold rating in a research report on Tuesday, November 8th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. Buy rating has been given by 9 analysts to the company stock whereas 1 analyst given UNDERPERFORM rating to stock and 9 analysts given HOLD rating.
Juno Therapeutics (NASDAQ:JUNO) traded down 10.63% during midday trading on Wednesday, hitting $22.62. 951,267 shares of the company's stock traded hands.
11/23/2016 - Juno Therapeutics, Inc. had its " rating reiterated by analysts at FBR Capital Markets.
Riyad Mahrez magic inspires Leicester to second win in a row
Leicester relied so heavily on team morale last season and evidently that was deteriorating as the weeks of the season went by. Hull City: Jakupovic; Elabdellaoui, Maguire, Ranocchia, Robertson; Huddlestone; Markovic, Clucas , Ndiaye, Grosicki; Niasse.
The company's price sits 23.02% above from its 50-day moving average of $21.35 and -12.38% below from the stock's 200-day moving average which is $25.08.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, March 1st. For the current quarter the company has high EPS estimates of $-0.74 in contradiction of low EPS estimates of $-0.91. The business earned $21.15 million during the quarter, compared to analyst estimates of $14.57 million. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015. The firm's quarterly revenue was up 409.6% on a year-over-year basis.
While looking at the Stock's Performance, Juno Therapeutics Inc. now shows a Weekly Performance of 2.26%, where Monthly Performance is 6%, Quarterly performance is 7.05%, 6 Months performance is -28.26% and yearly performance percentage is -47.08%.
This story was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of USA & global copyright law. 3,977,158 shares of the stock were exchanged. Finally, Ellington Management Group LLC acquired a new stake in Juno Therapeutics during the fourth quarter valued at approximately $198,000. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 1,296 shares in the last quarter. Metropolitan Life Insurance Co. First Trust Advisors LP now owns 929,305 shares of the biopharmaceutical company's stock valued at $27,888,000 after buying an additional 226,108 shares in the last quarter. Finally, Amalgamated Bank purchased a new position in shares of Juno Therapeutics during the second quarter valued at $309,000. Institutional investors own 61.80% of the company's stock. ABOUT JUNO Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. CAR-T therapy removes a key component of the immune system called T cells from a patient's blood and re-engineers them to more efficiently attack cancer before returning them to the patient.